¡°12 weeks' stopping rule¡± in the treatment of genotype 1 chronic hepatitis C: Two prognostic categories under the same label?

[Guest guest]

¡°12 weeks' stopping rule¡± in the treatment of genotype 1 chronic hepatitis C:

Two prognostic categories under the same label?

Authors: Jos M. Ladero a; Gustavo Lpez-Alonso a; Mara J. Devesa a; Francisca

Cuenca a; Marta greda a; Ortega b; Avelina Surez c; Daz-Rubio a

Affiliations: a Departments of Gastroenterology (Liver Unit),

b Pathology,

c Clinical Microbiology, Hospital Clnico San , Complutense University,

Madrid, Spain

DOI: 10.1080/00365520801989969

Publication Frequency: 12 issues per year

Published in: Scandinavian Journal of Gastroenterology, Volume 43, Issue 8 2008

, pages 979 - 983

First Published: 2008

Subjects: Gastroenterology; Gastrointestinal & Abdominal Surgery;

Formats available: HTML (English) : PDF (English)

Article Requests: Order Reprints : Request Permissions

Abstract

Objective. The current guidelines recommend maintenance of combined therapy for

hepatitis C virus (HCV) genotype-1 chronic hepatitis when HCV-RNA is

undetectable or ¡Â2 log10 of baseline after 12 weeks of therapy. The aim of this

study was to investigate whether the probability of obtaining sustained viral

(SVR) response is similar when HCV-RNA is undetectable or is present at ¡Â2

log10 level after 12 weeks of therapy. Material and methods. Retrospective

analysis was carried out in 208 HCV genotype-1 chronic hepatitis patients

treated with pegylated interferon and ribavirin with available data on HCV viral

load after 12 weeks of therapy and definite data on the results of therapy.

Results. Seventy-six (68.5%) out of 111 patients with undetectable HCV-RNA and 4

(11.8%) out of 34 patients with HCV-RNA ¡Â2 log10 from baseline at week 12

reached SVR (odds ratio 16.29, 95% CI 5.08-67.12; p

_________________________________________________________________

With Windows Live for mobile, your contacts travel with you.

http://www.windowslive.com/mobile/overview.html?ocid=TXT_TAGLM_WL_mobile_072008

[Guest guest]

¡°12 weeks' stopping rule¡± in the treatment of genotype 1 chronic hepatitis C:

Two prognostic categories under the same label?

Authors: Jos M. Ladero a; Gustavo Lpez-Alonso a; Mara J. Devesa a; Francisca

Cuenca a; Marta greda a; Ortega b; Avelina Surez c; Daz-Rubio a

Affiliations: a Departments of Gastroenterology (Liver Unit),

b Pathology,

c Clinical Microbiology, Hospital Clnico San , Complutense University,

Madrid, Spain

DOI: 10.1080/00365520801989969

Publication Frequency: 12 issues per year

Published in: Scandinavian Journal of Gastroenterology, Volume 43, Issue 8 2008

, pages 979 - 983

First Published: 2008

Subjects: Gastroenterology; Gastrointestinal & Abdominal Surgery;

Formats available: HTML (English) : PDF (English)

Article Requests: Order Reprints : Request Permissions

Abstract

Objective. The current guidelines recommend maintenance of combined therapy for

hepatitis C virus (HCV) genotype-1 chronic hepatitis when HCV-RNA is

undetectable or ¡Â2 log10 of baseline after 12 weeks of therapy. The aim of this

study was to investigate whether the probability of obtaining sustained viral

(SVR) response is similar when HCV-RNA is undetectable or is present at ¡Â2

log10 level after 12 weeks of therapy. Material and methods. Retrospective

analysis was carried out in 208 HCV genotype-1 chronic hepatitis patients

treated with pegylated interferon and ribavirin with available data on HCV viral

load after 12 weeks of therapy and definite data on the results of therapy.

Results. Seventy-six (68.5%) out of 111 patients with undetectable HCV-RNA and 4

(11.8%) out of 34 patients with HCV-RNA ¡Â2 log10 from baseline at week 12

reached SVR (odds ratio 16.29, 95% CI 5.08-67.12; p

_________________________________________________________________

With Windows Live for mobile, your contacts travel with you.

http://www.windowslive.com/mobile/overview.html?ocid=TXT_TAGLM_WL_mobile_072008